RecruitingNCT04883905
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
Sponsor
Alnylam Pharmaceuticals
Enrollment
150 participants
Start Date
Apr 26, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Eligibility
Min Age: 12 Years
Inclusion Criteria1
- Documented diagnosis of AHP, per physician's determination
Exclusion Criteria1
- Currently enrolled in a clinical trial for any investigational agent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(30)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04883905